Mozambique vs Uganda: Average cost of multi drug-resistant tuberculosis treatment
Mozambique
1,250 constant 2022 US$
in 2024
Uganda
1,209 constant 2022 US$
in 2024
Mozambique rank
37th
Uganda rank
39th
Average cost of multi drug-resistant tuberculosis treatment over time
- Mozambique
- Uganda
How they compare
Mozambique currently reports 1,250 constant 2022 US$ against 1,209 constant 2022 US$ in Uganda, a difference of 41 constant 2022 US$.
Across all 8 years both countries report, Mozambique has been ahead every year.
Mozambique ranks 37th and Uganda ranks 39th of 92 countries.
Mozambique has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Mozambique | Uganda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,095 constant 2022 US$ | 1,210 constant 2022 US$ | 1,885 constant 2022 US$ | Mozambique |
| 2020s | 2,464 constant 2022 US$ | 1,304 constant 2022 US$ | 1,160 constant 2022 US$ | Mozambique |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Mozambique or Uganda?
- Mozambique, at 1,250 constant 2022 US$ against 1,209 constant 2022 US$ in Uganda as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Mozambique and Uganda?
- 41 constant 2022 US$, with Mozambique ahead.
- How many years of comparable data are there for Mozambique and Uganda?
- 8 years are reported by both, from 2017 to 2024.
- How do Mozambique and Uganda rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Mozambique ranks 37th and Uganda ranks 39th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.